Our fair value estimate is TWD 370 per share, based on a discounted cash flow model using a weighted average cost of capital of 9%. This implies an adjusted price/earnings ratio of 30 times based on ...

The FDA has accepted the supplemental new drug application for decitabine/cedazuridine plus venetoclax to treat adults with AML.